Literature DB >> 10464248

Inhibition of the broad spectrum nonmetallocarbapenamase of class A (NMC-A) beta-lactamase from Enterobacter cloacae by monocyclic beta-lactams.

L Mourey1, L P Kotra, J Bellettini, A Bulychev, M O'Brien, M J Miller, S Mobashery, J P Samama.   

Abstract

beta-Lactamases hydrolyze beta-lactam antibiotics, a reaction that destroys their antibacterial activity. These enzymes, of which four classes are known, are the primary cause of resistance to beta-lactam antibiotics. The class A beta-lactamases form the largest group. A novel class A beta-lactamase, named the nonmetallocarbapenamase of class A (NMC-A) beta-lactamase, has been discovered recently that has a broad substrate profile that included carbapenem antibiotics. This is a serious development, since carbapenems have been relatively immune to the action of these resistance enzymes. Inhibitors for this enzyme are sought. We describe herein that a type of monobactam molecule of our design inactivates the NMC-A beta-lactamase rapidly, efficiently, and irreversibly. The mechanism of inactivation was investigated by solving the x-ray structure of the inhibited NMC-A enzyme to 1.95 A resolution. The structure shed light on the nature of the fragmentation of the inhibitor on enzyme acylation and indicated that there are two acyl-enzyme species that account for enzyme inhibition. Each of these inhibited enzyme species is trapped in a distinct local energy minimum that does not predispose the inhibitor species for deacylation, accounting for the irreversible mode of enzyme inhibition. Molecular dynamics simulations provided evidence in favor of a dynamic motion for the acyl-enzyme species, which samples a considerable conformational space prior to the entrapment of the two stable acyl-enzyme species in the local energy minima. A discussion of the likelihood of such dynamic motion for turnover of substrates during the normal catalytic processes of the enzyme is presented.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10464248     DOI: 10.1074/jbc.274.36.25260

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  5 in total

Review 1.  Current challenges in antimicrobial chemotherapy: focus on ß-lactamase inhibition.

Authors:  Carine Bebrone; Patricia Lassaux; Lionel Vercheval; Jean-Sébastien Sohier; Adrien Jehaes; Eric Sauvage; Moreno Galleni
Journal:  Drugs       Date:  2010-04-16       Impact factor: 9.546

2.  Enhancing resistance to cephalosporins in class C beta-lactamases: impact of Gly214Glu in CMY-2.

Authors:  Andrea Endimiani; Yohei Doi; Christopher R Bethel; Magdalena Taracila; Jennifer M Adams-Haduch; Alexandra O'Keefe; Andrea M Hujer; David L Paterson; Marion J Skalweit; Malcolm G P Page; Sarah M Drawz; Robert A Bonomo
Journal:  Biochemistry       Date:  2010-02-09       Impact factor: 3.162

3.  Syntheses and studies of new forms of N-sulfonyloxy β-lactams as potential antibacterial agents and β-lactamase inhibitors.

Authors:  Serena Carosso; Marvin J Miller
Journal:  Bioorg Med Chem       Date:  2015-08-14       Impact factor: 3.641

4.  Direct diazo-transfer reaction on beta-lactam: synthesis and preliminary biological activities of 6-triazolylpenicillanic acids.

Authors:  Po C Chen; Rebekah E Wharton; Pratiq A Patel; Adegboyega K Oyelere
Journal:  Bioorg Med Chem       Date:  2007-08-25       Impact factor: 3.641

Review 5.  Three decades of beta-lactamase inhibitors.

Authors:  Sarah M Drawz; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.